News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MEDA Receives Positive Opinion for Retigabine in Europe



1/24/2011 8:17:41 AM

GÖTEBORG, Sweden--(BUSINESS WIRE)-- Meda’s (STO:MEDAA) partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorization for retigabine, named ezogabine in the US, as an adjunctive (add-on) treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

Read at BioSpace.com


comments powered by Disqus
MEDA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES